Acura conducts research, development, laboratory, stability, quality assurance, manufacturing, warehousing and  other activities relating to the Aversion® Technology at its Culver, Indiana operations facility. Our facility is registered by the Drug Enforcement Agency (“DEA”) to perform research, development and the manufacture of certain Schedule II - V controlled substances in bulk and finished dosage forms. The 28,000 square foot facility is periodically inspected by the DEA and the FDA and currently conforms to all applicable regulations.